Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Health plans limit physical or occupational therapy sessions to as few as 20 a year, no matter the patient's infirmities.

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take ...

At this point, there are several therapies which are coming along, a large trial called the ExRx trial, which included the nutraceutical, nicotinamide riboside has finished. The data are not yet ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

Health plans often limit physical therapy to 20 or 30 sessions, even for people who may need months of treatment, multiple ...

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced its financial results for ...

New research finds, adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models.

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.

Imagine reducing your gym time to just 15 minutes and achieving results. EMS therapy could be the shortcut you’ve been ...

What medicines do you need prescriptions for and who is authorised to write those prescriptions is not a straight-forward ...